VAN WIJMEERSCH, Bart

Email Alert RSS Feed

Profile

Full Name
VAN WIJMEERSCH, Bart
Email
bart.vanwijmeersch@uhasselt.be
 
Loading... 5 0 5 0 false
Loading... 6 0 5 0 false

Publications

Refined By:
Date Issued:  [2020 TO 2022]
Author:  Comi, G.

Results 1-11 of 11 (Search time: 0.003 seconds).

Issue DateTitleContributor(s)TypeCat.
12022Cognitive improvements accompanied with WPAI improvements in OCR-treated patients with RRMS: 96-week CASTING dataVermersch, P.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Kuenzel, T.; Benedict, R.Journal ContributionM
22022Safety of Alemtuzumab in Patients with Multiple Sclerosis: Interim Results of a Post-Authorization Safety Study (PASS)Montalban, X.; VAN WIJMEERSCH, Bart; Gobbi, C.; Robertson, N.; Klotz, L.; Achiron, A.; Lee, A.; Eichau, S.; Vecsei, L.; Benzerdjeb, H.; Rodrigues, A.; Jurgensen, S.; Chirieac, M.; Comi, G.Journal ContributionM
32022Efficacy and safety of ocrelizumab is maintained in patients with RRMS with suboptimal response to prior disease-modifying therapies: 4-year NEDA data from CASTING-LIBERTOOreja-Guevara, C.; Benedict, R. H.; Comi, G.; Cutter, G.; Kister, I.; Siva, A.; Wiendl, H.; VAN WIJMEERSCH, Bart; Wuerfel, J.; El Azzouzi, B.; Buffels, R.; Dirks, P.; Kuenzel, T.; Vermersch, P.Journal ContributionM
42022Cognitive improvements in ocrelizumab-treated patients with relapsing-remitting multiple sclerosis: 96-week CASTING study dataBenedict, R. H.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Kuenzel, T.; Vermersch, P.Journal ContributionM
52022Employment and cognitive improvements in ocrelizumab-treated patients with relapsing-remitting multiple sclerosis: 96-week CASTING study dataWiendl, H.; Benedict, R. H.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Buffels, R.; Kuenzel, T.; Vermersch, P.Journal ContributionM
62022Employment and Cognitive Improvements in Ocrelizumab-Treated Patients with Relapsing-Remitting Multiple Sclerosis: 96-Week CASTING Study DataWiendl, H.; Benedict, R.H.B.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Buffels, R.; Kuenzel, T.; Vermersch, P.Conference MaterialC2
72021Efficacy and safety of ocrelizumab in patients with RRMS with suboptimal response to prior disease-modifying therapies: 3-year data from CASTING and LIBERTO 1-year interim resultsVAN WIJMEERSCH, Bart; Comi, G.; Oreja-Guevara, C.; Wiendl, H.; Wuerfel, J.; Buffels, R.; Dirks, P.; Kuenzel, T.; Kadner, K.; Vermersch, P.Journal ContributionM
82020Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study)Hartung, H-P; Comi, G.; Arnold, D. L.; Boyko, A. N.; Havrdova, E. K.; Inshasi, J. S.; McCombe, P.; Nakamura, K.; Oreja-Guevara, C.; Pelletier, D.; Pozzilli, C.; Selmaj, K. W.; Scott, T. F.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, BartJournal ContributionM
92020Efficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results)Vermersch, P.; Eralinna, J.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Wei, W.; Comi, G.Journal ContributionM
102020Alemtuzumab Outcomes Over 9 Years in RRMS Patients With Highly Active Disease From CARE-MS I and II (TOPAZ)Ziemssen, T.; Bass, A. D.; Berkovich, R.; Eichau, S.; Hobart, J.; Hunter, S. F.; Limmroth, V.; Pelletier, D.; Pozzilli, C.; Schippling, S.; Singer, B. A.; Sousa, L.; Traboulsee, A.; Uittlehaag, B. M. J.; VAN WIJMEERSCH, Bart; Poole, E. M.; Choudhry, Z.; Geertsen, S.; Daizadeh, N.; Comi, G.Journal ContributionM
112020Ocrelizumab phase iiib efficacy from casting: 2-year neda (mri re-baselined) subgroup rates in rrms patients with a suboptimal response to prior dmtsWiendl, H.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wuerfel, J.; Buffels, R.; Kadner, K.; Kuenzel, T.; Vermersch, P.Journal ContributionM